Kathryn A Fraser

Title: Kathryn A Fraser: Innovator in Tumor Microenvironment Research

Introduction

Kathryn A Fraser is a prominent inventor based in Saint Paul, MN (US). She has made significant contributions to the field of cancer research, particularly in understanding and manipulating the tumor microenvironment. With a total of 2 patents, her work focuses on innovative methods and compositions that enhance the effectiveness of cancer treatments.

Latest Patents

Fraser's latest patents include groundbreaking inventions related to the use of soluble β-glucan in cancer therapy. The first patent, titled "β-glucan methods and compositions that affect the tumor microenvironment," discusses the combination of soluble β-glucan and immune suppression-relieving agents. This combination promotes an immunostimulatory environment, enhancing the effectiveness of anti-angiogenics and checkpoint inhibitors. The second patent, "Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironment," further explores the synergistic effects of soluble β-glucan with anti-cancer agents, aiming to improve treatment outcomes for patients.

Career Highlights

Fraser is currently associated with Biothera Inc., where she continues to advance her research in cancer therapies. Her innovative approaches have positioned her as a key figure in the development of new treatment modalities that leverage the immune system to combat cancer.

Collaborations

Throughout her career, Kathryn has collaborated with notable colleagues, including Nandita Bose and Keith B Gorden. These partnerships have fostered a collaborative environment that enhances the research and development of effective cancer treatments.

Conclusion

Kathryn A Fraser's contributions to cancer research through her patents and collaborations highlight her commitment to improving patient outcomes. Her innovative work in the tumor microenvironment continues to pave the way for advancements in cancer therapy.